Abstract: Uveal melanoma (UM) is the most common primary intraocular malignancy in adults and is characterized by a high propensity for metastasis, particularly to the liver. The prognosis for metastatic UM is historically poor, necessitating the development of novel targeted therapies. Approximately 90% of UM cases harbor mutations in the GNAQ or GNA11 genes, which constitutively activate the Protein Kinase C (PKC) and mitogen-activated protein kinase (MAPK) signaling pathways. Darovasertib (LXS196) is a first-in-class, oral, small-molecule inhibitor that potently targets both classical and novel PKC isoforms. Clinical trials have demonstrated its efficacy in metastatic UM, both as a monotherapy and in combination with MEK inhibitors (binimetinib) or c-MET inhibitors (crizotinib). While darovasertib exhibits a favorable safety profile compared to older PKC inhibitors, its efficacy as a monotherapy is limited by its cytostatic nature and the development of resistance via the Hepatocyte Growth Factor (HGF)/c-MET pathway. This review synthesizes the current literature on darovasertib, detailing its pharmacological activity, molecular mechanism of action, structure-activity relationships, current limitations, and future perspectives in the treatment of uveal melanoma and beyond.
1. Introduction
Uveal melanoma (UM) is a rare but aggressive cancer, representing the most common primary intraocular malignancy in adults [1][2]. Despite advances in the local treatment of primary tumors, such as radiation and enucleation, approximately 40% to 50% of patients eventually develop metastatic disease, predominantly in the liver [1][2][3]. Once metastasis occurs, the prognosis is exceptionally poor, with survival rates dropping rapidly and a historical median overall survival (OS) of approximately 7 to 10 months [1][2].
Unlike cutaneous melanoma, UM has a distinct genetic profile characterized by a very low mutational burden and a lack of ultraviolet radiation mutational signatures [2]. The pathogenesis of UM is heavily driven by early activating mutations in the G protein subunit alpha q (GNAQ) or G protein subunit alpha 11 (GNA11) genes, which are present in about 90% of patients [1][3]. These mutations lead to the constitutive activation of downstream signaling cascades, most notably the Protein Kinase C (PKC) and MAPK pathways [1]. Because traditional chemotherapies and standard immune checkpoint inhibitors have shown limited efficacy in metastatic UM, targeting the PKC pathway has emerged as a critical therapeutic strategy [1][3]. Darovasertib (LXS196) is a novel, first-in-class PKC inhibitor that received Orphan Drug Designation from the U.S. FDA in May 2022 for the treatment of UM, representing a significant advancement in targeted therapy for this disease [1].
2. Pharmacological Activity
Darovasertib has demonstrated significant pharmacological activity in both preclinical models and clinical trials. In a Phase I clinical trial involving patients with metastatic UM, darovasertib monotherapy achieved an objective response rate (ORR) of 9.1% (including one complete response and five partial responses) and a disease control rate (DCR) of 75%, with 68.2% of patients achieving stable disease [2][3]. The median duration of response was 10.1 months [3]. Furthermore, the 1-year overall survival (OS) rate for patients treated with darovasertib monotherapy was 57%, with a median OS of 13.2 months, which is significantly greater than the historical median OS of 7 months in similar patient populations [1].
To enhance efficacy, darovasertib has been evaluated in combination regimens. When combined with the MEK inhibitor binimetinib, 79% of evaluated patients with metastatic UM experienced a decrease in tumor size [1]. Even more promising results have been observed when darovasertib is combined with the c-MET inhibitor crizotinib. In a Phase I/II trial, this combination yielded a confirmed partial response in 30% to 31% of patients and tumor shrinkage in 92% to 100% of evaluated patients [1][2]. The median progression-free survival (PFS) for the combination was 7 months, and in patients with hepatic-only disease, the median PFS extended to 11 months [3]. Notably, clinical efficacy was observed independently of the patients' HLA status [2][3].
3. Molecular Mechanism of Action
The molecular mechanism of darovasertib centers on its potent inhibition of the Protein Kinase C (PKC) family of serine/threonine kinases. Darovasertib is unique in its ability to inhibit both classical (α, β) and novel (δ, ϵ, η, θ) PKC isoforms [1][2]. In the pathophysiology of UM, mutations in GNAQ and GNA11 cause the constitutive activation of the Gα subunit, which in turn activates phospholipase C (PLCβ). PLCβ increases diacylglycerol (DAG) levels, recruiting and activating PKC isoforms, particularly PKCβ [1].
The activation of PKC subsequently triggers the RAS-dependent Rapidly Accelerated Fibrosarcoma (RAF)-1 protein kinase, leading to the activation of the extracellular signal-regulated kinase (ERK)/MAPK signaling cascade, which drives tumor cell proliferation and survival [1]. By selectively inhibiting PKC, darovasertib suppresses this downstream MAPK activation. In vitro studies have shown that darovasertib significantly decreases the levels of phosphorylated Myristoylated alanine-rich C-kinase substrate (pMARCKS), phosphorylated ERK (pERK), and pPKCδ, thereby halting the proliferation of UM cells [1].
4. Structure-Activity Relationship (SAR)
Darovasertib is a small molecule with the chemical name 3-Amino-N-[3-(amino-4-methylpiperdin-1-yl)pyridine-2-yl]-6-[3-(trifluoromethyl)pyridine-2-yl]pyrazine-2-carboxamide, and it has a molecular weight of 472.48 [1]. While exhaustive SAR data is limited in the provided literature, its structural design allows it to act as a highly potent, first-in-class inhibitor that targets a broader spectrum of PKC isoforms compared to earlier generation inhibitors.
Previous PKC inhibitors, such as sotrastaurin (AEB071) and enzastaurin, primarily targeted specific isoforms (e.g., PKC-α, β, and δ) but suffered from poor tolerability and limited clinical efficacy [1]. Sotrastaurin, for instance, failed to significantly decrease the biomarker levels of pMARCKS and pPKCδ at tolerable doses [1]. In contrast, the specific structural conformation of darovasertib enables it to potently inhibit both conventional and novel PKC isoforms at clinically achievable and tolerable plasma concentrations (e.g., 80 nM), leading to a more profound suppression of the downstream signaling pathways and a superior safety profile [1].
5. Current Limitations
Despite its clinical promise, the use of darovasertib is accompanied by several limitations. Pharmacologically, darovasertib is primarily cytostatic rather than cytotoxic. While it effectively induces cell cycle arrest and decreases cell proliferation by inhibiting MAPK activity, it does not directly induce cell death (apoptosis) in the majority of GNAQ/GNA11-mutant UM cell lines [1].
Furthermore, UM cells can develop resistance to PKC inhibition through parallel signaling pathways. The tumor microenvironment in UM often contains high levels of Hepatocyte Growth Factor (HGF), which binds to the c-MET receptor tyrosine kinase. Activation of the HGF/c-MET axis reactivates the MAPK and PI3K/AKT pathways, effectively bypassing PKC inhibition and antagonizing the effects of darovasertib [1]. This resistance mechanism necessitates the use of combination therapies, such as pairing darovasertib with c-MET inhibitors like crizotinib [1].
Regarding toxicity, darovasertib is associated with several treatment-related adverse events (TRAEs). The most frequent adverse effects include nausea (66.2% - 77.8%), diarrhea (45.6% - 61.1%), vomiting, fatigue, hypotension (22.1%), and elevated liver enzymes (ALT/AST) [1][3]. Grade 3 and 4 adverse events were reported in approximately 25% to 42.6% of patients [1][3]. However, comparative analyses indicate that darovasertib, alongside MEK inhibitors like trametinib and selumetinib, maintains a relatively favorable safety profile with a lower incidence of severe events compared to older PKC inhibitors and certain immunotherapies [3]. Twice-daily dosing (e.g., 300 mg BID) has been shown to be safer and more tolerable than once-daily dosing [1].
6. Future Perspectives
The future of darovasertib in oncology is highly promising, with several avenues of ongoing research. Because monotherapy is limited by resistance mechanisms, the most immediate future direction is the optimization of combination therapies. A Phase II/III clinical trial is currently underway to evaluate the combination of darovasertib and crizotinib as a first-line treatment for HLA-A*02:01-negative patients with metastatic UM [3].
Additionally, darovasertib is being investigated in earlier stages of the disease. A Phase II clinical trial (NCT05187884) is recruiting patients to determine the safety and efficacy of darovasertib as a neoadjuvant and adjuvant therapy for primary ocular melanoma, aiming to reduce tumor size prior to local therapy and delay or prevent recurrence [1].
Beyond uveal melanoma, darovasertib's mechanism of action suggests potential utility in other malignancies and conditions. It is currently being evaluated in basket trials for solid tumors harboring PRKC fusions or GNAQ/GNA11 mutations [1]. Preclinical studies are also exploring its use in combination with KRAS inhibitors (such as sotorasib and adagrasib) for the treatment of non-small cell lung cancer and hepatocellular carcinoma [1]. Interestingly, in vivo studies in mice have suggested that darovasertib may have neuroprotective effects; by decreasing the expression of glutamate transporter-1 (GLT-1), it reduces glutamate excitotoxicity, presenting a novel potential treatment avenue for cerebral ischemia and stroke [1].
